CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, today reported that an update on an ongoing phase II clinical study investigating the use of the Company’s lead product candidate, romidepsin (depsipeptide), in patients with metastatic hormone refractory prostate cancer (HRPC) was presented at the 31st European Society of Medical Oncology (ESMO) Congress being held in Istanbul, Turkey. The update was presented by Dr. Rhoda Molife, MRCP, MSc, MD, a Clinical Research Fellow in the Drug Development Unit of the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, UK.
